Pathophysiology and therapeutic strategy for late reproductive aged women with PCOS

晚育龄女性 PCOS 的病理生理学和治疗策略

基本信息

  • 批准号:
    10397427
  • 负责人:
  • 金额:
    $ 16.55万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2019
  • 资助国家:
    美国
  • 起止时间:
    2019-05-01 至 2024-04-30
  • 项目状态:
    已结题

项目摘要

Project Summary Polycystic ovary syndrome (PCOS) is a highly prevalent reproductive disorder characterized by hyperandrogenism (HA) and oligo/anovulation. PCOS is also associated with metabolic syndrome, obesity and insulin resistance. In young women with PCOS, several factors contribute to HA: a) excess luteinizing hormone (LH) secretion, b) abnormal ovarian steroidogenesis, c) abnormal adrenal steroidogenesis, and d) hyperinsulinemia/ insulin resistance. Of interest, HA (and menstrual function) improves with age in PCOS. However, the relative contributions of the aforementioned HA-related factors in young adult vs. late reproductive-aged women with PCOS are not known. Identifying the most important predictor(s) of HA in older women with PCOS will be critically important for devising the most relevant therapeutic strategies for older women with PCOS. While oral contraceptives (OCs) that are effective in addressing HA and menstrual dysfunction, they are also associated with adverse cardiovascular risks that may be further increased with age. Therefore, for older women with PCOS, alternative therapies (e.g., metformin) could be preferable. In young women with PCOS, metformin has been shown to be effective for treating menstrual dysfunction and biochemical HA. However, the relative desirability of OC vs. metformin is not known in older PCOS women. We propose to determine the relative contributions of four established predictors of HA (LH secretion, ovarian response to recombinant human chorionic gonadotropin administration, adrenal response to adrenocorticotropic hormone administration, and hyperinsulinemia) in older vs. young women with PCOS in a physiological study (Aim 1). We will also determine the relative desirability (as determined by quality of life assessments) of metformin vs. OCs in treating PCOS in women of late reproductive age in a randomized cross-over study (Aim 2). Successful completion of these studies will provide 1) a more complete and cohesive understanding of how the determinants of HA change with aging in PCOS; and 2) critical insight into age-relevant therapeutic strategies for older reproductive aged women with PCOS. The proposed studies in this K23 grant will be performed under the mentorship of Christopher R. McCartney, M.D., who has made significant contributions to understanding the pathophysiology of PCOS for the past 18 years. The research environment at my institution (University of Virginia) is very collaborative and supportive. With a tremendous research support and dedication from my mentor and my institution, I will continue to refine my research skills needed to become an independent clinical investigator.
项目摘要 多囊卵巢综合征(PCOS)是一种高度流行的生殖系统疾病,其特征在于: 高雄激素血症(HA)和少/无排卵。多囊卵巢综合征也与代谢综合征有关, 肥胖和胰岛素抵抗。在患有PCOS的年轻女性中,有几个因素导致HA:a) 黄体生成素(LH)分泌过多,B)卵巢类固醇生成异常,c)肾上腺皮质激素异常 类固醇生成,和d)高胰岛素血症/胰岛素抵抗。感兴趣的HA(和月经功能) 随着年龄的增长,PCOS然而,上述HA相关的相对贡献 年轻成年与生育年龄晚的PCOS妇女的因素尚不清楚。识别 在患有PCOS的老年女性中,HA的最重要预测因子对于设计 最相关的治疗策略与PCOS老年妇女。而口服避孕药 (OCs)有效解决HA和月经功能障碍,它们也与 不良心血管风险可能会随着年龄的增长而进一步增加。因此,对于老年妇女, PCOS,替代疗法(例如,二甲双胍)可能是优选的。在患有PCOS的年轻女性中, 二甲双胍已被证明可有效治疗月经功能障碍和生化HA。 然而,OC与二甲双胍的相对可取性在老年PCOS女性中尚不清楚。我们 建议确定HA的四个已建立的预测因子(LH分泌, 卵巢对重组人绒毛膜促性腺激素给药的反应,肾上腺对重组人绒毛膜促性腺激素给药的反应 促肾上腺皮质激素给药和高胰岛素血症), PCOS的生理研究(目的1)。我们还将确定相对可取性(如确定的 通过生活质量评估)二甲双胍与口服避孕药治疗晚期生殖道女性PCOS的比较 随机交叉研究中的年龄(目标2)。成功完成这些研究将提供1) 对HA的决定因素如何随着年龄的增长而变化的更完整和更有凝聚力的理解, 多囊卵巢综合征; 2)对老年生殖年龄的年龄相关治疗策略的重要见解 PCOS的女性在这个K23补助金拟议的研究将在指导下进行, Christopher R.麦卡特尼,医学博士,他为理解 在过去的18年里,PCOS的病理生理学。我所在机构的研究环境 (弗吉尼亚大学)是非常合作和支持。在巨大的研究支持下, 从我的导师和我的机构的奉献精神,我将继续完善我的研究技能, 成为一名独立的临床研究者。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Su H. Kim其他文献

Su H. Kim的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Su H. Kim', 18)}}的其他基金

Pathophysiology and therapeutic strategy for late reproductive aged women with PCOS
晚育龄女性 PCOS 的病理生理学和治疗策略
  • 批准号:
    9922339
  • 财政年份:
    2019
  • 资助金额:
    $ 16.55万
  • 项目类别:
Pathophysiology and therapeutic strategy for late reproductive aged women with PCOS
晚育龄女性 PCOS 的病理生理学和治疗策略
  • 批准号:
    10163692
  • 财政年份:
    2019
  • 资助金额:
    $ 16.55万
  • 项目类别:
Pathophysiology and therapeutic strategy for late reproductive aged women with PCOS
晚育龄女性 PCOS 的病理生理学和治疗策略
  • 批准号:
    10626723
  • 财政年份:
    2019
  • 资助金额:
    $ 16.55万
  • 项目类别:
Role of hyperandrogenemia in abnormal pubertal gonadotropin-releasing hormone (GnRH) secretion and development of PCOS
高雄激素血症在青春期促性腺激素释放激素(GnRH)分泌异常和多囊卵巢综合征(PCOS)发展中的作用
  • 批准号:
    9122655
  • 财政年份:
    2017
  • 资助金额:
    $ 16.55万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 16.55万
  • 项目类别:
    Fellowship
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 16.55万
  • 项目类别:
    Continuing Grant
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 16.55万
  • 项目类别:
    Research Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 16.55万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 16.55万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 16.55万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 16.55万
  • 项目类别:
    EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 16.55万
  • 项目类别:
    Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 16.55万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 16.55万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了